NCT05583916
Recruiting
Not Applicable
Phase I Safety and Feasibility Pilot Study of Same-Day Discharge After Video-Assisted Thoracoscopic Surgery (VATS) Anatomical Lung or Wedge Resection (VALUE Trial)
McGill University Health Centre/Research Institute of the McGill University Health Centre1 site in 1 country20 target enrollmentSeptember 7, 2022
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Lung Cancer
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Enrollment
- 20
- Locations
- 1
- Primary Endpoint
- Readmission Rate
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
Phase I to evaluate the safety and feasibility of same-day discharge in selected participants undergoing minimally-invasive lung surgery and who receive an enhanced recovery pathway.
Investigators
Jonathan Spicer
Assistant Professor of Surgery
McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria
Inclusion Criteria
- •Signed or verbal informed consent by participant
- •Male and female adults, age 18 and above
- •Clinical stage I-II lung cancer (suspected, proven, unproven), or secondary pulmonary malignancy
- •BMI \< 35
- •Eligible for surgery and lung cancer resection (FEV1 \> 60%, DLCO \> 60%)
- •Elective VATS anatomic resection (segmentectomy or lobectomy), or wedge resection
- •Capable caregiver for discharge home
Exclusion Criteria
- •Clinical stage III lung cancer
- •Surgery requiring pneumonectomy
- •Neoadjuvant therapy
- •Active pregnancy or breastfeeding
- •History of chronic pain syndromes
- •History of chronic opioid use
- •Concomitant major surgery indicated with current admission to hospital
- •Anticipated intraoperative complication including conversion to thoracotomy, major bleeding requiring blood transfusion, extensive adhesiolysis, injury to mediastinal structures, airway injury, nerve injury (phrenic, recurrent)
- •Need for epidural or patient-controlled intravenous analgesia
- •Need for urinary catheter
Outcomes
Primary Outcomes
Readmission Rate
Time Frame: 30 days post surgery
Rate of presentation to the emergency room after surgery
Time Frame: 30 days post surgery
Adverse Event Rate
Time Frame: 30 days post surgery
Same Day Discharge Rate
Time Frame: Throughout the trial, from start until completion of surgery for all the patients, up to 12 months.
Secondary Outcomes
- Percent of eligible participants consented(From trial start until last patient consented, up to 12 months.)
- Functional Assessment of Cancer Therapy - Lung (FACT-L)(30 days post surgery)
- Edmonton Symptom Assessment Scale (ESAS)(30 days post surgery)
- Duration of indwelling chest tube catheter(30 days post surgery or until the chest tube is removed (whichever comes last, assessed until 90 days post surgery))
- Rate of screen failure(From trial start until last patient consented, up to 12 months.)
- Pathway adherence rate(From moment of consent until 1 day post surgery.)
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Not Applicable
Safety and Feasibility of Early Discharge for Transfemoral Transcatheter Aortic Valve ReplacementAortic Valve StenosisNCT03600935BC Centre for Improved Cardiovascular Health315
Completed
Not Applicable
Safety And Feasibility of Early DischargE - a Prospective And Randomized Trial of Low-risk Primary Percutaneous Coronary Intervention (PCI) PatientsMyocardial InfarctionNCT00474214Hamilton Health Sciences Corporation54
Completed
Not Applicable
Same Day Discharge for Wedge ResectionSurgeryMinorLung CancerNCT05067738Lawson Health Research Institute54
Completed
Not Applicable
Safety of Same Day Discharge After Elective Percutaneous Coronary InterventionAngioplastyCoronaryNCT02214082Indus Hospital and Health Network210
Unknown
Not Applicable
Safety of Early Discharge Following Low Risk Myocardial InfarctionMyocardial InfarctionNCT01868256Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau1,558